Cantabio Pharmaceuticals, Inc.
Limited financial coverage for CTBO.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
About the company
Cantabio Pharmaceuticals, Inc. is a preclinical stage biotechnology company, which engages in the commercialization of novel therapies and the intellectual property generated from the research and development activities for Parkinson's, Alzheimer's diseases, and any other related diseases. It focuses on identification and development of small molecule pharmacological chaperones targeting proteins that misfold and aggregated in vivo vivo levels of proteins which display loss of function during disease conditions.
- CEO
- Gergely Tóth
- IPO
- 1995
- Employees
- 451
- HQ
- Palo Alto, GA, US
Price Chart
- 52W High
- $1.01
- 52W Low
- $1.01
- 50D MA
- $1.01
- 200D MA
- $1.01
- Beta
- 456.60
- Avg Volume
- 10
Get TickerSpark's AI analysis on CTBO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our CTBO coverage
Recent articles, reports, and earnings notes.
No research on CTBO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CTBO report →Similar companies
Peers in the same neighborhood.